
hCG (Human Chorionic Gonadotropin)
hCG is a prescription hormone injection used in fertility treatment, in boys with undescended testicles, and in males with low testosterone from a pituitary cause. Combined with FSH it restores sperm production in most men with that condition, though often below normal levels. It does not help weight loss: its labels, FDA, a meta-analysis and a placebo-controlled trial agree, and "homeopathic" hCG drops are illegal. Its use with testosterone therapy is off-label and supported mainly by small studies of hormone levels and semen counts.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Women in supervised fertility treatment, males with hypogonadotropic hypogonadism (including those trying to father a child), and selected boys with undescended testicles, under a specialist
Common dosing range
Set by your prescriber. Labeled regimens vary by use: for example 5,000 to 10,000 USP units once, one day after the last dose of other fertility hormones, for ovulation; 500 to 4,000 USP units two or three times a week for months in males with hypogonadotropic hypogonadism
When to expect effects
Ovulation: within days of the trigger injection. Sperm production in hypogonadotropic hypogonadism: on average about 12 months in pooled studies
Watch out for
No boxed warning. In women: ovarian hyperstimulation syndrome (OHSS), blood clots, multiple pregnancy and ovarian torsion. In boys: early puberty. Allergic reactions including anaphylaxis. Contraindicated with prostate or other androgen-dependent cancers and early puberty (Novarel and generic labels); the Novarel label says it may cause fetal harm in pregnancy, and the Pregnyl label says it is not indicated in pregnancy. Not approved or effective for weight loss; over-the-counter hCG products are illegal
What is it
Human chorionic gonadotropin (hCG) is a hormone made by the placenta in pregnancy. As a medicine it is a prescription injection, approved by FDA. Novarel (5,000 and 10,000 USP unit vials), Pregnyl (10,000 USP units) and a generic chorionic gonadotropin (10,000 USP units, Fresenius Kabi) are purified from the urine of pregnant women and injected into a muscle; Ovidrel (choriogonadotropin alfa) is a lab-made version injected under the skin for fertility treatment. The urinary hCG labels approve three uses: undescended testicles in boys before puberty when nothing physically blocks their descent, selected cases of low testosterone caused by a pituitary problem (hypogonadotropic hypogonadism) in males, and triggering ovulation in women whose ovaries do not release eggs, after treatment with other fertility hormones. The same labels state in capital letters that hCG has not been shown to be an effective addition to obesity treatment. FDA says there are no FDA-approved hCG products for weight loss and that hCG is not approved for use without a prescription. Its use alongside testosterone therapy in men is off-label.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
triggering final egg maturation in IVF and ICSI fertility treatment Good Evidence | In fresh cycles with a woman's own eggs: higher live birth rate than a GnRH agonist trigger (OR 0.47 for agonist versus hCG), with more OHSS | Women in supervised IVF or ICSI cycles | Egg retrieval or ovulation follows within days of the injection |
weight loss with a very low-calorie diet (the "hCG diet") Good Evidence | No difference from placebo in weight loss, hunger or fat distribution | None shown | No benefit seen over 6 weeks |
sperm production in men with hypogonadotropic hypogonadism Limited Evidence | Sperm production restored in about 74% to 78% of men; mean concentration about 10 to 12 million per mL | Men with low LH and FSH from a pituitary or hypothalamic cause, especially with onset after puberty, treated with hCG plus FSH | About 12 to 18 months |
undescended testicles (cryptorchidism) in boys Limited Evidence | About 24% complete descent in one meta-analysis; not better than placebo in another | Selected boys, as decided by a pediatric urologist | Weeks, over a course of injections |
preserving testicular function in men on testosterone therapy (off-label) Limited Evidence | Testicular testosterone kept near baseline with 250 to 500 IU every other day for 3 weeks | Men on testosterone therapy who want to keep fertility, under a specialist | Weeks for hormone levels; months for semen measures |
triggering final egg maturation in IVF and ICSI fertility treatment
- Effect
- In fresh cycles with a woman's own eggs: higher live birth rate than a GnRH agonist trigger (OR 0.47 for agonist versus hCG), with more OHSS
- Best fit
- Women in supervised IVF or ICSI cycles
- Time
- Egg retrieval or ovulation follows within days of the injection
weight loss with a very low-calorie diet (the "hCG diet")
- Effect
- No difference from placebo in weight loss, hunger or fat distribution
- Best fit
- None shown
- Time
- No benefit seen over 6 weeks
sperm production in men with hypogonadotropic hypogonadism
- Effect
- Sperm production restored in about 74% to 78% of men; mean concentration about 10 to 12 million per mL
- Best fit
- Men with low LH and FSH from a pituitary or hypothalamic cause, especially with onset after puberty, treated with hCG plus FSH
- Time
- About 12 to 18 months
undescended testicles (cryptorchidism) in boys
- Effect
- About 24% complete descent in one meta-analysis; not better than placebo in another
- Best fit
- Selected boys, as decided by a pediatric urologist
- Time
- Weeks, over a course of injections
preserving testicular function in men on testosterone therapy (off-label)
- Effect
- Testicular testosterone kept near baseline with 250 to 500 IU every other day for 3 weeks
- Best fit
- Men on testosterone therapy who want to keep fertility, under a specialist
- Time
- Weeks for hormone levels; months for semen measures
Evidence for 5 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
triggering final egg maturation in IVF and ICSI fertility treatment
Disease adjunctA 2014 Cochrane review of 17 randomized trials compared a GnRH agonist trigger with an hCG trigger in IVF cycles using a GnRH antagonist. In fresh cycles using a woman's own eggs, the agonist gave a lower live birth rate than hCG (odds ratio 0.47, 95% CI 0.31 to 0.70; 5 trials, 532 women; moderate-quality evidence): for a woman with a 31% chance of live birth with hCG, the chance with the agonist would be 12% to 24%. But hCG carried more OHSS: for a 5% risk with hCG, the risk with the agonist would be between nil and 2% (odds ratio 0.15; moderate-quality evidence). In donor-recipient cycles, the review found no evidence of a difference in live birth (1 trial, 212 women), while OHSS was again lower with the agonist. A 2016 Cochrane review of 18 trials (2,952 women) found no clear difference in ongoing pregnancy or live birth between lab-made and urinary hCG (odds ratio 1.15, 95% CI 0.89 to 1.49; 7 trials, 1,136 women; moderate-quality evidence), and no difference in OHSS; pharmaceutical companies funded 9 of the 18 trials.
Bottom line: In fresh IVF cycles using a woman's own eggs, an hCG trigger gives more live births than a GnRH agonist trigger but more OHSS; no difference was found between urinary and lab-made hCG.
weight loss with a very low-calorie diet (the "hCG diet")
No benefit foundA 1995 meta-analysis of 8 controlled and 16 uncontrolled trials of hCG with the Simeons very low-calorie diet found most studies were of poor quality; of the 12 studies scoring 50 or more points for quality (all controlled), only one reported hCG as a useful adjunct. The authors concluded that hCG does not bring about weight loss or fat redistribution, reduce hunger, or improve well-being. In a double-blind trial, 40 women with a BMI over 30 followed the same 5,000 kJ a day diet and received daily injections of hCG or saline 6 days a week for 6 weeks; those on hCG showed no advantage over placebo on any measure, including weight, hunger and body circumferences. Weight loss in these programs comes from the calorie restriction.
Bottom line: hCG does not add weight loss beyond the very low-calorie diet it is sold with.
sperm production in men with hypogonadotropic hypogonadism
Biomarker supportA 2025 meta-analysis of 41 studies (1,673 men with gonadotropin deficiency, mean age 25) found that after a median of 18 months of gonadotropin treatment, the average sperm concentration reached 11.6 million per mL. Any sperm appeared in 78% of men, more than 5 million per mL in 36% and more than 20 million per mL in 15%. Combined hCG and FSH gave more sperm than hCG alone, while testosterone levels and testicular size rose similarly with both. A 2026 meta-analysis of 50 studies (1,583 men with azoospermia) found sperm production restored in 74% after a mean of 11.8 months, and a pregnancy rate of 52% among couples wanting a child; most included studies were of poor methodological quality. An earlier meta-analysis found a 75% success rate and that previous testosterone therapy did not affect the result.
Bottom line: hCG, especially combined with FSH, restores sperm production in most men with pituitary-related hypogonadism, though counts often stay below normal.
undescended testicles (cryptorchidism) in boys
Disease adjunctThe evidence is weak and conflicting. A 2016 meta-analysis of 13 randomized trials found that hCG raised the rate of complete testicular descent compared with control, with a success rate of 24%, an effect seen in boys with both testicles undescended but not with one; the authors said hormones cannot be recommended for everyone because of low success rates and possible long-term harms. A 2018 meta-analysis of 7 low-quality trials found hCG no more effective than placebo (risk ratio 7.74, 95% CI 0.14 to 425.72; 2 trials, 31 boys). The 2014 American Urological Association guideline states that hormonal therapy is not recommended and that orchiopexy (surgery) is the most successful treatment. The labels also note that in most cases the response to hCG is temporary.
Bottom line: hCG moves undescended testicles down in only a minority of boys, often temporarily, and current US guidance prefers surgery.
Evidence is mixed
One meta-analysis of 13 trials found a modest benefit (24% success), while another of 7 trials found no benefit over placebo, and the AUA guideline does not recommend hormonal therapy.
preserving testicular function in men on testosterone therapy (off-label)
Biomarker supportThis is not an FDA-approved use. In a 3-week randomized study, 29 healthy men received 200 mg testosterone enanthate weekly with saline or hCG 125, 250 or 500 IU every other day. LH and FSH fell to 5% and 3% of baseline, and with testosterone plus saline, testosterone inside the testes fell by 94%. After treatment, testosterone inside the testes was 25% below baseline with 125 IU, 7% below with 250 IU and 26% above with 500 IU. In a retrospective review of 26 hypogonadal men (mean age 35.9) on testosterone plus hCG 500 IU every other day, followed for a mean of 6.2 months, semen measures did not change, no man became azoospermic, and 9 of the 26 contributed to a pregnancy. Neither study had a group on testosterone alone followed for fertility outcomes, and long-term safety was not studied.
Bottom line: Small studies suggest low-dose hCG keeps the testes working during testosterone therapy, but this off-label use lacks controlled fertility trials.
How it works
How to take it
What to track
Bottom line: A specialist-supervised injection whose dose and schedule your prescriber sets; it is not a weight-loss or over-the-counter product.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
No boxed warning on the current Novarel, Pregnyl or generic chorionic gonadotropin labels. Ovarian hyperstimulation syndrome (OHSS) in women: a rapid shift of fluid into the belly and chest that can include blood clots, breathing problems and kidney effects. It can develop quickly, peaks about 7 to 10 days after treatment, is more common and more severe if pregnancy occurs, and severe OHSS may be life-threatening. The label says to assess women for at least two weeks after the hCG dose.
Blood clots and lung complications: blood clots in veins or arteries, both with and without OHSS, have followed gonadotropin therapy, including pulmonary embolism, stroke and arterial blockage leading to loss of a limb, and rarely heart attack or death. Serious lung conditions such as acute respiratory distress syndrome have also been reported. Women with a personal or family history of clots, severe obesity or thrombophilia may be at higher risk.
Multiple pregnancy, ovarian torsion, ruptured ovarian cysts and ectopic pregnancy in fertility treatment: the labels list multiple births with all gonadotropin therapy, twisting of the ovary, enlargement or rupture of ovarian cysts with internal bleeding, and a higher rate of ectopic pregnancy in women using assisted reproduction.
Allergic reactions: anaphylaxis has been reported with urinary-derived hCG products, and hypersensitivity reactions include rash, hives, swelling (angioedema) and shortness of breath. The diluent supplied with the vials contains benzyl alcohol, which the labels say has been linked to a fatal "gasping syndrome" in premature infants and is not for use in newborns.
Early puberty in boys treated for undescended testicles, because hCG raises androgen levels; the labels say to stop treatment if signs of precocious puberty appear. The Novarel label also notes sporadic reports of testicular tumors in otherwise healthy young men receiving hCG for secondary infertility, without an established causal link.
Harms reported with hCG for weight loss: FDA says it has received reports of serious adverse events with hCG injections used for weight loss, including pulmonary embolism, depression, cerebrovascular problems, cardiac arrest and death. The very low-calorie diets (often 500 calories a day) sold with hCG products raise the risk of gallstones, electrolyte imbalance and irregular heartbeat. A case report describes a first manic episode in a 32-year-old woman right after a 45-day course of under-the-tongue hCG for weight loss; a causal link could not be proven.
Who should avoid it
- People with early (precocious) puberty, prostate cancer or another androgen-dependent tumor, or a past allergic reaction to hCG: contraindicated on the Novarel and generic labels
- Per the Pregnyl label: women with high FSH showing primary ovarian failure; anyone with uncontrolled thyroid, adrenal or pituitary disorders; tumors of the hypothalamus or pituitary, of the ovary, breast or uterus in women, or of the breast or prostate in men; reproductive organ malformations or fibroids incompatible with pregnancy; or abnormal vaginal bleeding of unknown cause
- People with heart or kidney disease, high blood pressure, epilepsy, migraine or asthma should use it only with caution, because hCG-driven androgens can cause fluid retention
Pregnancy & breastfeeding
Pregnancy: the contraindications section of the Novarel label says hCG may cause fetal harm when given to a pregnant woman; in mice, combined hCG and pregnant mare's serum caused high rates of birth defects, and whether this applies to humans is not known. The Pregnyl label says it is not indicated in pregnancy, may be used for luteal phase support but is stopped once pregnancy is confirmed, and that there are no data on hCG use in pregnancy. Breastfeeding: both labels say it is not known whether hCG passes into human milk and that caution should be used in a nursing woman; the Pregnyl label adds that the benefits of breastfeeding should be weighed with the mother's need for the drug. Talk with your doctor about pregnancy plans and feeding your baby.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Does hCG help with weight loss?⌄
No. The prescription labels state that hCG has not been shown to be effective in treating obesity and that there is no substantial evidence it adds weight loss beyond calorie restriction, changes fat distribution, or reduces hunger. A meta-analysis and a 6-week placebo-controlled trial in 40 women found no benefit. FDA says any loss on hCG diets comes from the severe calorie restriction.
Are hCG diet drops legal?⌄
No. FDA says there are no FDA-approved hCG products for weight loss, that hCG is not approved for use without a prescription, and that all drug products claiming to include "homeopathic" hCG are illegally marketed. FDA and the FTC sent warning letters to sellers of such drops, pellets and sprays.
Why do some men on testosterone therapy use hCG?⌄
Testosterone therapy shuts down the hormones that tell the testes to make sperm and their own testosterone. Small studies found low-dose hCG kept testicular testosterone near normal for 3 weeks and kept semen measures stable in 26 men over about 6 months. This use is off-label and has no large controlled trials, so it is a decision for you and a specialist.
What is hCG approved for?⌄
The labels approve it for undescended testicles in boys before puberty when nothing physically blocks descent, selected cases of low testosterone caused by a pituitary problem in males, and triggering ovulation in women who do not ovulate, after other fertility hormones. Ovidrel, a lab-made form, is approved for fertility treatment including IVF.
Can I take hCG with my supplements or other medicines?⌄
The hCG labels list no drug interactions, there are no studies of hCG with supplements, and our database lists no supplement or food interactions for it. The labels do say hCG can interfere with laboratory tests for LH, so tell the lab you are on it. Ask your doctor or pharmacist to check your full list, including supplements.
Is hCG safe for women in fertility treatment?⌄
It is widely used under supervision, but the labels warn of ovarian hyperstimulation syndrome, which can be severe, blood clots, multiple pregnancy and ovarian torsion. Your fertility team monitors you with ultrasound and blood tests, and the Pregnyl label says women should be watched for OHSS for at least two weeks after the hCG dose.
References by claim
sperm production in men with hypogonadotropic hypogonadism
triggering final egg maturation in IVF and ICSI fertility treatment
undescended testicles (cryptorchidism) in boys
weight loss with a very low-calorie diet (the "hCG diet")
preserving testicular function in men on testosterone therapy (off-label)
Safety
Pregnyl (chorionic gonadotropin) prescribing information · DailyMed (FDA label) link
Novarel (chorionic gonadotropin) prescribing information · DailyMed (FDA label) link
Questions and Answers on HCG Products for Weight Loss · FDA link
Avoid Dangerous HCG Diet Products (FDA Consumer Update) · FDA link
Sanches et al., 2014 · PubMed (2014) link
Chorionic gonadotropin for injection prescribing information (Fresenius Kabi) · DailyMed (FDA label) link
Track hCG (Human Chorionic Gonadotropin) with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
